Gastroesophageal Reflux Disease News and Research

RSS

Gastroesophageal reflux disease (GERD) is a more serious form of gastroesophageal reflux (GER), which is common. GER occurs when the lower esophageal sphincter (LES) opens spontaneously, for varying periods of time, or does not close properly and stomach contents rise up into the esophagus. GER is also called acid reflux or acid regurgitation, because digestive juices—called acids—rise up with the food. The esophagus is the tube that carries food from the mouth to the stomach. The LES is a ring of muscle at the bottom of the esophagus that acts like a valve between the esophagus and stomach.

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

AGA issues Medical Position Statement on Treatment of Barrett's Esophagus

BARRX Medical, Inc., a leader in developing minimally invasive medical devices to remove precancerous tissue from the gastrointestinal tract, reported today that the American Gastroenterological Association has issued the AGA Medical Position Statement on the Treatment of Barrett's Esophagus.

10 Mar 2011

New guidelines to address major clinical issues encountered in treatment of Barrett's esophagus

Endoscopic removal of pre-cancerous cells in patients with confirmed, high-risk Barrett's esophagus is recommended rather than surveillance, according to a new "Medical Position Statement on the Management of Barrett's Esophagus," published by the American Gastroenterological Association (AGA) Institute. The medical position statement was published in Gastroenterology, the official journal of the AGA Institute.

1 Mar 2011

EGS publishes three clinical studies on TIF procedure over past four months

EndoGastric Solutions, the leader in the emerging field of Natural Orifice Surgery (NOS), announced that three clinical studies on transoral fundoplication have been published over the past four months.

18 Feb 2011

Scott & White Healthcare offers TIF procedure to patients with chronic heartburn

Millions of Americans, or 10 percent of the population, suffers from daily heartburn or other symptoms of reflux such as regurgitation, chronic cough, hoarseness and dental erosions. Until recently, many of these patients faced either a lifetime of daily medications, incomplete resolution, or worsening of their symptoms while treatment options were often limited to surgery.

16 Feb 2011

Study finds heartburn as a common condition in Iceland

Heartburn is a signature symptom of gastroesophageal reflux disease (GERD), which is a cluster of symptoms and signs associated with regurgitation of stomach acid up to the pharynx and mouth. Patient-based studies of GERD have shown high prevalence and chronicity, particularly in Western societies. GERD is associated with significant health-care utilization and diminished quality of life.

8 Feb 2011

FDA issues Complete Response Letter for approval of Eisai's rabeprazole sodium extended-release capsules

Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.

2 Feb 2011

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator.

1 Feb 2011

FDA approves Matrix's generic Protonix DR Tablets ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Pantoprazole Sodium Delayed-release (DR) Tablets USP, 20 mg (base) and 40 mg (base), the generic version of Wyeth's Protonix® DR Tablets, a treatment for the irritation of the esophagus caused by gastroesophageal reflux disease (GERD).

25 Jan 2011

Physicians who completed internal medicine training lack primary care knowledge: Study

Doctors who have completed training in internal medicine are in general poorly prepared for jobs as primary care physicians, most notably lacking the knowledge to best care for patients with chronic conditions such as diabetes, hypertension and high cholesterol, new Johns Hopkins research suggests.

12 Jan 2011

Intellipharmaceutics announces delay of patent approvement to market Protonix drug

Intellipharmaceutics International, today announced that it has notified the U.S. Food and Drug Administration that it has not received notification, as provided for under the Hatch-Waxman Act, of any patent infringement proceedings by the brand owner, Wyeth Pharmaceuticals, a wholly-owned subsidiary of Pfizer, for its application to market a generic of Wyeth's Protonix® tablets.

22 Dec 2010

NinePoint enters IP licensing agreement with Massachusetts General Hospital

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, NinePoint has certain exclusive rights in multiple fields to 188 patents and patent applications owned by MGH.

13 Dec 2010

Digestive Disease Specialists deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Digestive Disease Specialists, Inc. has selected its ProVation MD software for gastroenterology procedure documentation and coding.

9 Dec 2010

Cook Medical's controlled-release esophageal stent receives FDA clearance

Cook Medical's controlled-release esophageal stent fully covered in silicone has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), making available yet another advanced solution from Cook Medical, the only full-line supplier of endoscopic devices.

9 Nov 2010

Mederi's second generation Stretta and Secca Systems granted CE Mark approval

Mederi Therapeutics Inc announced today that it has received a CE Mark authorizing the European distribution and use of Mederi's second generation of the Stretta and Secca Systems. The Stretta System is for treatment of gastric reflux disease, commonly known as GERD, and the Secca System is for treatment of bowel control disorder, or BCD. These latest systems include a streamlined user interface, significant improvements in ease of use, and are smaller, lighter, and highly portable.

8 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Studies explore impact of upper GI conditions on sleep

The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleep—and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleep—were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

18 Oct 2010

Intellipharmaceutics announces FDA acceptance to file ANDA for Protonix generic version

Intellipharmaceutics International Inc. today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Protonix (delayed release pantoprazole sodium).